@prefix this: . @prefix sub: . @prefix drugbank: . @prefix np: . @prefix mondo: . @prefix pav: . @prefix infores: . @prefix xsd: . @prefix ntemplate: . @prefix orcid: . @prefix rdfs: . @prefix pmid: . @prefix ncit: . @prefix rdf: . @prefix biolink: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { drugbank:DB01175 a biolink:Drug; rdfs:label "escitalopram"; biolink:category biolink:Drug . mondo:0008114 a biolink:Disease; rdfs:label "obsessive-compulsive disorder"; biolink:category biolink:Disease . sub:association rdf:object mondo:0008114; rdf:predicate biolink:treats; rdf:subject drugbank:DB01175; a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation; rdfs:label "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]."; biolink:aggregator_knowledge_source infores:knowledge-collaboratory; biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation; biolink:has_population_context sub:context; biolink:publications pmid:30101713; biolink:relation ncit:C94303 . sub:context a biolink:Cohort; rdfs:label "adults"; biolink:category biolink:Cohort . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB"; npx:hasSignature "PVsL+yEE5Nsi+zVQtMT5N+DrHb4vbNHsbuhBPors+w1mbZIGCe7HmtvoJ3RQm4aUMwU14uisPy1PiKff49zxkKra6uoWE0biyS7WmZGj3Cr7gTPVKo+ebWAVKzy7F4rinpYucZOqDamc811jGl8vbOlH8vR6sqL5rnFYZYT/Glk="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2022-09-16T11:53:46.825298"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-1501-1082; ntemplate:wasCreatedFromTemplate . biolink: pav:version "2.3.0" . }